Navigation Links
Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL
Date:9/5/2008

al activity of belinostat has been observed in an ongoing Phase II trial of belinostat monotherapy in patients with recurrent or refractory cutaneous (CTCL) or peripheral T-cell lymphoma (PTCL). Efficacy is being analyzed separately in PTCL and CTCL patients. In 11 patients evaluable for response in the PTCL arm, 2 durable complete responses (CR) and 4 Stable Diseases (SD) have been observed as announced at "10th International Conference on Malignant Lymphoma" in Lugano in June. In both arms of the study, the objective response rate in the first stage has met the criteria for expansion to the second stage of a Simon 2-stage design.

Objectives and methods of evaluation The primary study endpoint will be objective response rate (ORR). Objective response is complete response (CR) or partial response (PR) based on independent radiology review. Secondary objectives of the study are to determine: safety of belinostat monotherapy, time to response, duration of response, time to progression (TTP), progression-free survival (PFS), one-year progression-free rate, one-year survival rate and overall survival (OS).

Today's news does not change TopoTarget's full-year financial guidance for 2008.

Background information

About Periferal T-Cell Lymphomas (PTCL)

PTCL represent approximately 10% of all non-Hodgkin's lymphomas (NHL) in Western populations and are associated with a poor prognosis. Most patients with PTCL relapse after initial treatment with cytotoxic agents, and 5-year survival is less than 30%. T-cell Non Hodkins Lymphomas, to which PTCL belongs, are associated with a poorer outcome and survival compared to the B-cell lymphomas. The primary response rate for all PTCL subtypes remains at less than 60%, with nearly all patients relapsing. Median survival of all PTCL patients (excluding a few subtypes) is approximately 3-4 years, with a 5-year survival of less than 30%. There are currently no therapies approved specifically for PTCL. Prim
'/>"/>

SOURCE TopoTarget
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Ondine Announces Presentation of Positive Clinical Trial Results at the American Academy of Periodontologys 94th Annual Meeting
2. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
3. SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms
4. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
5. Ondine Announces Publication of Positive Results from Pseudomonas aeruginosa Eradication Study
6. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
7. Thought Leaders Discuss Positive Outlook for Bapineuzumab in Alzheimers Disease in MedPredict Report
8. Positive clinical data for PBI-1402 presented at the Annual Congress of the European Hematology Association
9. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
10. QLT announces positive Health Canada decision on Aczone(R)
11. Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... 29, 2015  Caris Life Sciences ® , ... promise of precision medicine, today announced the presentation ... clinical utility of Caris Molecular Intelligence ® , ... helping to identify targeted treatment options for patients ... the studies, results of which are to be ...
(Date:5/29/2015)... SPRING, Md. and RESEARCH TRIANGLE PARK, ... Corporation (NASDAQ: UTHR ) announced today that Roger ... Therapeutics, will provide an overview and update on the company,s ... New York City . The presentation ... Thursday, June 4, 2015, at 11:00 AM Eastern Time, and ...
(Date:5/29/2015)... May 29, 2015 Seoul Semiconductor ... in LED technology, on May 28th announced that ... share by strengthening its high efficient and high ... , Since 2011 Seoul Semiconductor has developed efficient ... market and has supplied LEDs for headlamps to ...
(Date:5/28/2015)... 28, 2015 Research ... addition of Jain PharmaBiotech,s new report  "Alzheimer ...  to their offering.       (Logo: ... challenge in management. With nearly 8 million ... major markets of the world and anticipated ...
Breaking Biology Technology:Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 2Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 3Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 4Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 5Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 6Seoul Semiconductor Increases the Global Automotive LED Market Share with its High Efficient and Reliable LEDs for Automotive Lightings 2Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 2Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 3
... Boston Scientific,Corporation (NYSE: BSX ) today announced financial ... as guidance for net sales and,earnings per share (EPS) for ... -- Reported net sales of $1.978 billion and adjusted ... market leadership -- Achieved worldwide cardiac rhythm management (CRM) ...
... Holding Company to Strengthen ... Acquires Research and Product Development Company to Expedite Product ... ... at 8:00 am E.T., NEW YORK, Oct. 21 /Xinhua-PRNewswire-FirstCall/ -- American Oriental,Bioengineering, ...
... $165 Million Line of Credit to ... Amylin, ... ) and Eli Lilly and Company (NYSE: LLY ),today announced they have ... if approved, would,become the first once weekly therapy to treat type 2 diabetes. ...
Cached Biology Technology:Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 2Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 3Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 4Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 5Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 6Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 7Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 8Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 9Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 10Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 11Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 12Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 13Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 14Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 15Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 16Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 17Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 18Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 19Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 20Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 21Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 22Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 23Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 24Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 25Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 26Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 27American Oriental Bioengineering Completes Two Acquisitions 2American Oriental Bioengineering Completes Two Acquisitions 3American Oriental Bioengineering Completes Two Acquisitions 4Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly 2Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly 3
(Date:4/20/2015)... The announcement comes as demand ... Management (GRM), Ireland,s foremost records management ... built up an impressive track record of clients within the ... the records management sector in Dubai . ... staffbase and employ a further eight staff members at its ...
(Date:4/14/2015)... , April 14, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... nominated for the 2015 New York Design Awards under ... Design100, New York City Design Awards are part of ... on over 2,500 ratings from the marketplace, industry and ...
(Date:4/10/2015)... DUBLIN , April 10, 2015 ... the addition of the "Security Competitive Profiles - ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , NEC will continue to ... solutions to the market, with a company focus on ... solution anticipated. Winning opportunities in the ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3NEC Security Competitive Profile 2015 2
... CA, November 20, 2008Scientists from the Scripps Research Institute ... anthracis , the bacterium that causes anthrax, to become ... for the development of treatments for bacterial infections. ... of the journal PLoS Pathogens . The ...
... currents could be a new, reliable and affordable alternative energy ... that works like a fish to turn potentially destructive vibrations ... is called VIVACE. A paper on it is published in ... Mechanics and Arctic Engineering . VIVACE is the first ...
... Associated Professor, DSc Barbara Ann Halkier, Department of ... Life Sciences, University of Copenhagen, has been granted ... award for her excellent research into secondary metabolites, ... plants. In particular, her research has focused ...
Cached Biology News:Scripps research scientists identify blood component that turns bacteria virulent 2Scripps research scientists identify blood component that turns bacteria virulent 3'Fish technology' draws renewable energy from slow water currents 2'Fish technology' draws renewable energy from slow water currents 3The Danisco Award 2008 goes to D.Sc. Barbara Ann Halkier from Faculty of Life Sciences, Copenhagen 2
...
...
... and anti-viral agent. Inhibits several important steps of ... of HUVEC cells. Also reduces intracellular reactive oxygen ... release of endothelial cells. Formula: ... O 8 MolWeight: ...
22 x 50 mm; No. 1 thickness range: 0.13 to 0.17 mm, suitable for work in histology, cytology, urinalysis and microbiology, precleaned, store at room temperature ...
Biology Products: